Hypertension: A review and rationale of treatment

Disease-a-Month

Volumn 51, Issue 10-11, 2005, Pages 548-614

  Copley, John Brian ^a   Rosario, Reinaldo ^a  

^a DEPARTMENT OF COLORECTAL SURGERY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CHLORTALIDONE; DIHYDROPYRIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; FOSINOPRIL; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; LISINOPRIL; LOSARTAN; PERINDOPRIL; PRAVASTATIN; RAMIPRIL; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; UNINDEXED DRUG; VALSARTAN; VERAPAMIL;

AFRICAN AMERICAN; AGE DISTRIBUTION; BRADYCARDIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE CONTROL; DISEASE EXACERBATION; DRESSLER SYNDROME; DRUG DOSE REDUCTION; ETHNIC DIFFERENCE; FATIGUE; HEART BLOCK; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE CONTRACTILITY; HISTORY; HUMAN; HYPERKALEMIA; HYPERTENSION; INSULIN SENSITIVITY; KIDNEY DISEASE; KIDNEY FAILURE; META ANALYSIS; METABOLIC SYNDROME X; MICROALBUMINURIA; OXYGEN CONSUMPTION; PROTEINURIA; RECURRENT DISEASE; REVIEW; RISK FACTOR; SEX DIFFERENCE; SEXUAL DYSFUNCTION; SIDE EFFECT; SILENT MYOCARDIAL ISCHEMIA; SLEEP DISORDER; SODIUM RESTRICTION; STABLE ANGINA PECTORIS; SYSTEMATIC REVIEW; TACHYCARDIA; TREATMENT CONTRAINDICATION; TREATMENT PLANNING; WEIGHT REDUCTION;

EID: 29144506962     PISSN: 00115029     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.disamonth.2005.10.004     Document Type: Article

References (193)

1. M. Ezzati, A.D. Lopez, A. Rogers Comparative Risk Assessment Collaborative Group Selected major risk factors and global and regional burden of disease Lancet 360 2002 1347 1360
2. F. Volhard, T. Fahr Die Brightsche Nierenkrankheit Klinik Pathologie und Atlas 1914 Julius Springer Berlin, Germany 247 280
3. F.H. Messerli This day 50 years ago N Engl J Med 332 1995 1029 1030
4. D. Hoel, R.B. Howard Hypertension, stalking the silent killer Postgrad Med 101 1997 1 8
5. R.W. Gifford FDR and hypertension if we'd only known then what we know now Geriatrics 51 1996 29 32
6. R.W. Gifford Three decades of antihypertensive therapy Clin Pharm Therap 28 1980 1 5
7. V.L. Burt, P. Whelton, E.J. Roccella Prevalence of hypertension in the US adult population results from the Third National Health and Nutrition Examination Survey, 1988-1991 Hypertension 25 1995 305 313
8. A.V. Chobanian, G.L. Bakris, H.R. Black The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Hypertension 42 2003 1206 1252
9. M.J. Glover, K.J. Greenlund, C. Ayala Racial/ethnic disparities in prevalence, treatment and control of hypertension - United States 1999-2002. Center for Disease Control MMWR 54 2005 7 9
10. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Arch Intern Med 157 1997 2413 2446
11. M. Moser, J.R. Guyther, F. Finnerty Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure JAMA 237 1977 255 261
12. SHEP Cooperative Research Group, Clinical Trials Branch Prevention of stroke by antihypertensive drug treatment in older patients with isolated systolic hypertension final results of the Systolic Hypertension in the Elderly Program (SHEP) JAMA 265 1991 3255 3264
13. C.D. Mulrow, J.A. Cornell, C.R. Herrera Hypertension in the elderly. Implication and generalizability of randomized trials JAMA 272 1994 1932 1938
14. American Heart Association 2003 Heart and Stroke Statistical Update. At: www.americanheart.org.
15. U.S. Renal Data System, USRDS 2004 Annual Data Report Atlas of end-stage renal disease in the United States National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD, 2004. Am J Kid Dis suppl 1 2005 S1 S270
16. Kidney Disease Outcomes Quality Initiative (K/DOQI) K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease Am J Kid Dis 43 suppl 2004 S1 S290
17. L.E. Fields, V.L. Burt, J.A. Cutler The burden of adult hypertension in the United States 1999 to 2000, a rising tide Hypertension 44 2004 398 404
18. National Institutes of Health NHLBI issues new high blood pressure clinical practice guidelines 2003 NIH News, May 14,. Available at: www.nih.gov/news/pr/may2003/nhlbi-14.htm.
19. S.S. Franklin, M.J. Jacobs, N.D. Wong Predominence of isolated systolic hypertension among middle-aged and elderly US hypertensives. Analysis based on National Health and Nutrition Examination Survey (NHANES) III Hypertension 37 2001 869 874
20. S. Lewington, R. Clarke, N. Qizilbash Age-specific relevance of usual blood pressure to vascular mortality a meta-analysis of individual data of one million adults in 61 prospective studies Lancet 360 2002 1903 1913
21. Blood Pressure Lowering Treatment Trialists' Collaboration Effects of different blood-pressure-lowering regimens on major cardiovascular events results of prospectively-designed overviews of randomized trials Lancet 362 2003 1527 1535
22. National High Blood Pressure Education Program Working Group Report on Primary Prevention of Hypertension Arch Intern Med 153 1993 186 208
23. J.D. Neaton, D.N. Wentworth, J. Cutler Multiple Risk Factor Intervention Trial Research Group Risk factors for death from different types of stroke Ann Epidemiol 3 1993 493 499
24. R.S. Vasan, M.G. Larson, E.P. Leip Impact of high-normal blood pressure on the risk of cardiovascular disease N Engl J Med 345 2001 1291 1297
25. W.B. Kannel Risk stratification in hypertension new insights from the Framingham Study Am J Hypertens 13 2000 3S 10S
26. T.H. Jafar, P.C. Stark, C.H. Schmid Progression of chronic kidney disease the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition Ann Intern Med 139 2003 244 252
27. G.L. Bakris, M.R. Weir, S. Shanifer Effects of blood pressure level on progression of diabetic nephropathy. Results from the RENAAL study Arch Intern Med 163 2003 1555 1565
28. M.J. Sarnak, T. Greene, X. Wang The effect of a lower target blood pressure on the progression of kidney disease long-term follow-up of the Modification of Diet in Renal Disease Study Ann Intern Med 142 2005 342 351
29. P. Ruggenenti, A. Perna, G. Loriga Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2) multicentre, randomized controlled trial Lancet 365 2005 939 946
30. J.T. Wright Jr, G. Bakris, T. Greene Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease results from the AASK trial JAMA 288 2002 2421 2431
31. A.S. Levey, C.D. Mulrow An editorial update what level of blood pressure control in chronic kidney disease? Ann Intern Med 143 2005 79 81
32. C. Hsu, C.E. McCulloch, J. Darbinian Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease Arch Intern Med 165 2005 923 928
33. C.M. Dezji A retrospective study of persistence with single-pill combination therapy versus concurrent two-pill combination therapy in patients with hypertension Managed Care 9 suppl 9 2000 206
34. J.G. Douglas, G.L. Bakris, M. Epstein Management of high blood pressure in African Americans. Consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks Arch Intern Med 163 2003 525 541
35. S. Julius, S.E. Kjeldsen, M. Weber VALUE trial group Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine the VALUE randomized trial Lancet 363 2004 2022 2031
36. R.J. Gibbons, J. Abrams, K. Chatterjee ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-summary article a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Chronic Stable Angina) J Am Coll Cardiol 41 2003 159 168
37. R. Ferrari, F. Cucchini, R. Bolognesi How do calcium antagonists differ in clinical practice? Cardiovasc Drugs Ther 8 1994 565 575
38. M.W. Gilman, W.B. Kannel, A. Belanger Influence of heart rate on mortality among persons with hypertension The Framingham Study Am Heart J 125 1993 1148 1154
39. C.J. Pepine, E.M. Handberg, R.M. Cooper-DeHoff A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial JAMA 290 2003 2805 2816
40. G. Mancia, R.M. Cooper-DeHoff, A.C. Hewkin Association of BP control and frequency of mortality and CV morbidity in hypertensive patients with CAD The International Verapamil SR-Trandolapril Study Am J Hypertension 17 2004 116A
41. L.H. Lindholm, H. Ibsen, B. Dahlof Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) a randomized trial against atenolol Lancet 359 2002 1004 1010
42. Heart Outcomes Prevention Evaluation Study Investigators Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus results of the HOPE study and MICRO-HOPE substudy Lancet 355 2000 253 259
43. S.E. Nissen, E.M. Tuzcu, P. Libby Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT study: a randomized controlled trial JAMA 292 2004 2217 2226
44. C.J. Pepine What is the optimal blood pressure and drug therapy for patients with coronary artery disease? JAMA 292 2004 2271 2273
45. Sever P, Dahlof B, Poulter N. The Anglo-Scandinavian Cardiac Outcomes Trial. A randomized controlled trial of the prevention of coronary heart disease and other vascular events by blood pressure and cholesterol reduction in a factorial study design. Presented at the American College of Cardiology Annual Scientific Session, March 2005, Orlando, FL.
46. Heart Outcomes Prevention Evaluation Study Investigators Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients N Engl J Med 342 2000 145 153
47. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) JAMA 288 2002 2981 2997
48. R. Garg, S. Yusuf for the Collaborative Group on Ace Inhibitor Trials Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure JAMA 273 1995 1450 1456
49. M. Packer, M.B. Fowler, E.B. Roecker Effect of carvedilol on the morbidity of patients with severe chronic heart failure results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study Circulation 106 2002 2194 2199
50. M. Packer, A.J. Coats, M.B. Fowler Effect of carvedilol on survival in severe chronic heart failure N Engl J Med 344 2001 1651 1658
51. B. Pitt, F. Zannad, W.J. Remme The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators N Engl J Med 341 1999 709 717
52. B. Pitt, W. Remme, F. Zannad Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 2003 1309 1321
53. M.A. Pfeffer, K. Swedberg, C.B. Granger CHARM Investigators and Committees Effects of candesartan on mortality and morbidity in patients with chronic heart failure the CHARM-Overall programme Lancet 362 2003 759 766
54. J.N. Cohn, G. Tognoni Valsartan Heart Failure Trial Investigators A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure N Engl J Med 345 2001 1667 1675
55. A.P. Maggioni, I. Anand, S.O. Gottlieb Val-HeFT Investigators Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors J Am Coll Cardiol 40 2002 1414 1421
56. M.A. Pfeffer, J.J. McMurray, E.J. Velazquez Valsartan in Acute Myocardial Infarction Trial Investigators Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both N Engl J Med 349 2003 1893 1906
57. A.L. Taylor, S. Ziesche, C. Yancy African-American Heart Failure Trial Investigators Combination of isosorbide dinitrate and hydralazine in blacks with heart failure N Engl J Med 351 2004 2049 2057
58. A.H. Wu, L. Parsons, N.R. Every Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction a report from the Second National Registry of Myocardial Infarction (NRMI-2) J Am Coll Cardiol 40 2002 1389 1394
59. P.G. Steg, O.H. Dabbous, L.J. Feldman Global Registry of Acute Coronary Events (GRACE) Investigators Determinants and prognostic impact of heart failure complicating acute coronary syndromes observations from the Global Registry of Acute Coronary Events (GRACE) Circulation 109 2004 494 499
60. P. Buck, S.A. Rasmussen, S.Z. Gildstrom The long-term impact of the angiotensin-converting enzyme inhibitor trandolapril on mortality and hospital admissions in patients with left ventricular dysfunction after a myocardial infarction follow-up to 12 years Eur Heart J 26 2004 145 152
61. C. Torp-Pedersen, L. Kober Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation Lancet 354 1999 9 12
62. I. Gustafsson, C. Torp-Pederson, L. Kober Trace Study Group Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction J Am Coll Cardiol 34 1999 83 89
63. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure Lancet 342 1993 821 828
64. P. Vantrimpont, J.L. Rouleau, A. Ciampi Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study Eur Heart J 19 1998 1552 1563
65. E. Ambrosioni, C. Borghi, B. Magnani The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study Investigators N Engl J Med 332 1995 80 85
66. K. Abbott, E. Basta, G.L. Bakris Blood pressure control and nephroprotection in diabetes J Clin Pharmacol 44 2004 431 438
67. G.L. Bakris, M.R. Weir Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine Is this a cause for concern? Arch Intern Med 160 2000 685 693
68. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). Available at www.acc.org/clinical/ guidelines/unstable/incorporated/index.htm.
69. E.M. Antman, D.T. Anbe, P.W. Armstrong ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction executive summary: a report of the ACC/AHA Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines on the Management of Patients with Acute Myocardial Infarction) J Am Coll Cardiol 44 2004 671 719
70. C.J. Pepine, G. Faich, R. Mahuck Verapamil use in patients with cardiovascular disease an overview of randomized trials Clin Cardiol 21 1998 633 641
71. T.C. Fagan, J. Sowers Type 2 diabetes mellitus greater cardiovascular risks and greater benefits of therapy Arch Intern Med 159 1999 1033 1034
72. T.M. Davis, H. Millns, F.M. Stratton Risk factors for stroke in type 2 diabetes mellitus United Kingdom Prospective Diabetes Study (UKPDS 29) Arch Intern Med 159 1999 1097 1103
73. L.S. Geiss, D.B. Rolka, M.M. Engelgau Elevated blood pressure among U.S. adults with diabetes, 1988-1994 Am J Prev Med 22 2002 42 48
74. J. Stamler, O. Vaccaro, J. Neaton Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial Diabetes Care 16 1993 434 444
75. A.I. Adler, I.M. Stratton, H.A. Neil Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36) prospective observational study BMJ 321 2000 412 419
76. I.M. Stratton, A.I. Adler, H.A. Neil Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35) prospective observational study BMJ 321 2000 405 412
77. L. Hannson, A. Zanchetti, S.G. Carruthers, B. Dahlof, D. Elmfeldt, S. Julius HOT Study Group Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principle results of the Hypertension Optimal Treatment (HOT) randomized trial Lancet 351 1998 1755 1762
78. G. Eknoyan, T. Hostetter, G.L. Bakris Proteinuria and other markers of chronic kidney disease a position statement of the National Kidney Foundation (NKF) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Am J Kid Dis 42 2003 617 622
79. C.A. Jones, M.E. Francis, M.S. Eberhardt Microalbuminuria in the U.S. population third National Health and Nutrition Examination Survey Am J Kid Dis 39 2002 445 459
80. W.F. Keene, G. Eknoyan Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE) a position paper of the National Kidney Foundation Am J Kid Dis 33 1999 1004 1010
81. American Diabetes Association Standards of Medical Care in Diabetes Diabetes Care 27 suppl 1 2004 S15 S35
82. G.L. Bakris, M. Williams, L. Dworkin Preserving renal function in adults with hypertension and diabetes a consensus approach Am J Kid Dis 36 2000 646 661
83. American Diabetes Association Hypertension management in adults with diabetes Diabetes Care 27 suppl 1 2004 S65 S67
84. K. Borch-Johnsen, B. Feldt-Rasmussen, S. Strandgaard Urinary albumin excretion. An independent predictor of ischemic heart disease Arterioscler Thromb Vasc Biol 19 1999 1992 1997
85. J.P. Gang, G.L. Bakris Microalbuminuria marker of vascular dysfunction, risk for cardiovascular disease Vasc Med 7 2002 35 43
86. K. Tuttle Cardiovascular implications of albuminuria J Clin Hypertens (Greenwich) 6 suppl 3 2004 13 17
87. K. Wachtell, H. Ibsen, M.H. Olsen Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy the LIFE Study Ann Intern Med 139 2003 901 906
88. S.F. Dinneen, H.C. Gerstein The association of microalbuminuria and mortality in non-insulin dependent diabetes mellitus. A systematic overview of the literature Arch Intern Med 157 1997 1413 1418
89. P. Ruggenenti, A. Fassi, A. Parianova-Ilieva Preventing microalbuminuria in type 2 diabetes N Engl J Med 351 2004 1941 1951
90. The BENEDICT Group The Bergamo Nephrologic Diabetes Complication Trial (BENEDICT) design and baseline characteristics Control Clin Trials 24 2003 442 461
91. F.W. Asselbergs, G.F. Diercks, H.L. Hillege Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria Circulation 110 2004 2809 2816
92. H. Ibsen, K. Wachtell, M.H. Olsen Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy J Hypertension 22 2004 1805 1811
93. H. Miettinen, S.M. Haffner, S. Lehto Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects Stroke 27 1996 2033 2039
94. D. de Zeeuw, G. Remuzzi, H.H. Parving Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy Circulation 110 2004 921 927
95. American Diabetes Association Diabetic nephropathy Diabetes Care 25 suppl 1 2002 S85 S89
96. The UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes UKPDS 38 BMJ 317 1998 703 713
97. J. Tuomilehto, D. Rastenyte, W.H. Birkenhager Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators N Engl J Med 340 1999 677 684
98. P.K. Whelton, J. Barzilay, W.C. Cushman Clinical outcomes in antihypertensive treatment on type 2 diabetes, impaired fasting glucose concentration, and normoglycemia Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Arch Intern Med 165 2005 1401 1409
99. R. Fernandez, J.G. Puig, J.C. Rodriguez-Perez Effect of two antihypertensive combinations on metabolic control in type 2 diabetic hypertensive patients with albuminuria a randomized, double-blind study J Hum Hypertens 15 2001 849 856
100. K.T. Khaw, N. Warehow, R. Luben Glycated hemoglobin, diabetes and mortality in men in Norfolk Cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk) BMJ 322 2001 15 18
101. M. Schneider, M. Lerch, M. Papiri Metabolic neutrality of combined verapamil-trandolapril treatment in contrast to beta-blocker-low-dose chlorthalidone treatment in hypertensive type 2 diabetics J Hypertens 14 1996 669 677
102. G.L. Bakris, V. Fonseca, R.E. Katholi GEMINI Investigators Metabolic effects of carvedilol vs metroprolol in patients with type 2 diabetes mellitus and hypertension, a randomized controlled trial JAMA 292 2004 2227 2236
103. H.R. Black, W.J. Elliott, G. Grandits Principle results of the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) trial JAMA 289 2003 2073 2082
104. R.O. Estacio, B.W. Jeffers, W.R. Hiatt The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension N Engl J Med 338 1998 645 652
105. L.H. Lindholm, H. Ibsen, K. Borch-Johnson LIFE study group Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study J Hypertension 20 2002 1879-6
106. M.J. Brown, C.R. Palmer, A. Castaigne Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study Intervention as a Goal in Hypertension Treatment (INSIGHT) Lancet 356 2000 366 372
107. L. Hansson, L.H. Lindholm, L. Niskanen Effect of angiotensin-converting- enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension the Captopril Prevention Project (CAPPP) randomized trial Lancet 353 1999 611 616
108. L.E. Eberly, J.D. Cohen, R. Prineas Multiple Risk Factor Intervention Trial Research Group Impact of incident diabetes and incident nonfatal cardiovascular disease on 18-year mortality the multiple risk factor intervention trial experience Diabetes Care 26 2003 848 854
109. F.B. Hu, M.J. Stampfer, S.M. Haffner Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes Diabetes Care 25 2002 1129 1134
110. P. Verdecchia, G. Reboldi, F. Angeli Adverse prognostic significance of new diabetes in treated hypertensive subjects Hypertension 43 2004 963 969
111. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final Report 2002 National Institutes of Health, National Heart, Lung, and Blood Institute NIH Publication No. 02-5215, September
112. J. Chen, P. Munter, L.L. Hamm The metabolic syndrome and kidney disease Ann Intern Med 140 2004 167 174
113. World Health Organization Definition, diagnosis, and classification of diabetes mellitus and its complications. Part 1. Diagnosis and classification of diabetes mellitus 1999 Geneva:
114. AACE. New ICD-9-cm code for dysmetabolic syndrome X. Available at www.aace.com/members/socio/syndromex.php.
115. S. Malik, N.D. Wong, S.S. Franklin Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults Circulation 110 2004 1245 1250
116. H.M. Lakka, D.E. Laaksonen, T.A. Lakka The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men JAMA 288 2002 2709 2716
117. P.W. Wilson, R.B. D'Agostino, H. Parise The metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus Diabetes 51 2002 A242
118. E.S. Ford, W.H. Giles, W.H. Dietz Prevalence of the metabolic syndrome among US adults. Findings from the Third National Health and Nutrition Examination Survey JAMA 287 2002 356 359
119. C.M. Alexander, P.B. Landsman, S.M. Teutsch NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older Diabetes 52 2003 1210 1214
120. K.M. Narayan, J.P. Boyle, T.J. Thompson Lifetime risk for diabetes mellitus in the United States JAMA 290 2003 1884 1889
121. D. Levy, R.J. Garrison, D.D. Savage Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study N Engl J Med 322 1990 1561 1566
122. P. Verdecchia, C. Porcellati, G. Reboldi Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension Circulation 104 2001 2039 2044
123. M.J. Roman, T.G. Pickering, J.E. Schwartz Association of carotid atherosclerosis and left ventricular hypertrophy J Am Coll Cardiol 25 1995 83 90
124. B. Dahlof, R.B. Devereux, S.E. Kjeldsen Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in hypertension study (LIFE) a randomized trial against atenolol Lancet 359 2002 995 1003
125. PROGRESS Collaborative Group Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack Lancet 358 2001 1033 1041
126. F. Forette, M.L. Seux, J.A. Staessen Prevention of dementia in randomized double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial Lancet 352 1998 1347 1351
127. A.S. Levey, J. Coresh, E. Balk National Kidney Foundation practice guidelines for chronic kidney disease evaluation, classification, and stratification Ann Intern Med 139 2003 137 147
128. A.S. Levey, J. Coresh K/DOQI Clinical Practice Guidelines for chronic kidney disease evaluation, classification and stratification Am J Kid Dis 39 suppl 1 2002 S1 S266
129. A.S. Levey, T. Greene, J.W. Kusek A simplified equation to predict glomerular filtration rate from serum creatinine J Am Soc Neph 11 2000 155A (abstr).
130. G. Remuzzi, P. Ruggenenti, A. Benigni Understanding the nature of renal disease progression Kid Intern 51 1997 2 15
131. M. Abbate, C. Zoja, D. Corna In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation J Am Soc Neph 9 1998 1213 1224
132. P.E. DeJong, B.M. Brenner From secondary to primary prevention of progressive renal disease the case for screening for albuminuria Kid Intern 66 2004 2109 2110
133. W.F. Keane, B.M. Brenner, D. De Zeeuw The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy The RENAAL Study Kid Intern 63 2003 1499 1507
134. K. Iseki, Y. Ikemiya, C. Iseki Proteinuria and the risk of developing end-stage renal disease Kid Intern 63 2003 1468 1474
135. G.L. Bakris, M.R. Wier, M. Secic Differential effects of calcium antagonist subclasses on markers of nephropathy progression Kid Intern 65 2004 1991 2002
136. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) Randomized placebo-controlled trial of the effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy Lancet 349 1997 1857 1863
137. P. Ruggenenti, A. Perna, G. Gherardi Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria Lancet 354 1999 359 364
138. P. Ruggenenti, A. Perna, G. Gherardi Chronic proteinuric nephropathies outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury Am J Kid Dis 35 2000 1155 1165
139. P.E. De Jong, S. Anderson, D. de Zeeuw Glomerular preload and afterload reduction as a tool to lower urinary protein leakage will such treatments also help to improve renal function outcome? J Am Soc Nephrol 3 1993 1333 1341
140. M. Praga, E. Hernandez, C. Montoyo Long-term beneficial effects of angiotensin-converting enzyme inhibition in patients with nephrotic proteinuria Am J Kid Dis 20 1992 240 248
141. G.L. Bakris, A. Mangrum, J.B. Copley Effect of calcium channel or beta blockade on the progression of diabetic nephropathy in African Americans Hypertension 29 1997 744 750
142. J.C. Peterson, S. Adler, J.M. Burkart Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study Ann Intern Med 123 1995 754 762
143. T. Shiigai, M. Shichiri Late escape from the antiproteinuric effect of ACE inhibition in diabetic renal disease Am J Kid Dis 37 2001 477 483
144. J. Lea, T. Greene, L. Hebert African American Study of Kidney Disease and Hypertension Study Group The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease results of the African American study of kidney disease and hypertension Arch Intern Med 165 2005 1947 1953
145. E.J. Lewis, L.G. Hunsicker, R.P. Bain The Collaborative Study Group The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy N Engl J Med 329 1993 1456 1462
146. B.M. Brenner, M.E. Cooper, D. de Zeeuw Effects of losartan on renal and cardiovascular outcomes in patients with type 2 Diabetes and nephropathy N Engl J Med 345 2001 861 869
147. E.J. Lewis, L.G. Hunsicker, W.R. Clarke Renoprotective effect of angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 2001 851 860
148. P. Ruggenenti, A. Perna, G. Remuzzi Retarding progression of chronic renal failure the neglected issue of residual proteinuria Kid Intern 63 2003 2254 2261
149. B.M. Brenner, J. Zagrobelny Clinical renoprotective trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors Kid Intern 63 suppl 83 2003 S77 S85
150. G. Maschio, D. Alberti, G. Janin Effect of the angiotensin-converting- enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group N Engl J Med 334 1996 939 945
151. P. Ruggenenti, A. Perna, G. Gherardi on behalf of GISEN Group Renal function and requirements for dialysis in chronic nephropathy patients on long-term ramipril REIN follow-up trial Lancet 352 1998 1252 1256
152. P. Ruggenenti, A. Perna, G. Remuzzi ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results J Am Soc Neph 12 2001 2832 2837
153. I. Giatras, J. Lau, A.S. Levey Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group Ann Intern Med 127 1997 337 345
154. T.H. Jafar, C.H. Schmid, M. Landa Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease Ann Intern Med 135 2001 73 87
155. L. Golan, J.D. Birkmeyer, H.G. Welch The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors Ann Intern Med 131 1999 660 667
156. ACE Inhibitors in Diabetic Nephropathy Trialist Group Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin- converting enzyme inhibitors? Ann Intern Med 134 2001 370 379
157. H.H. Parving, H. Lehnert, J. Brochner-Mortensen Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes N Engl J Med 345 2001 870 878
158. G. Viberti, N.H. Wheeldon Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus a blood pressure-independent effect Circulation 106 2002 672 678
159. N. Nakao, A. Yoshimura, H. Morita Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE) a randomized controlled trial Lancet 361 2003 117 124
160. M. Rosenberg, C. Hsu Chronic kidney disease and progression. Nephrology Self-Assessment Program Am Soc Nephrol 3 2004 296 333
161. R. Campbell, F. Sangalli, E. Perticucci Effects of combined ACE inhibitor and angiotension II antagonist treatment in human chronic nephropathies Kid Intern 63 2003 1094 1103
162. P. Rutkowski, L. Tylicki, M. Renke Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis Am J Kid Dis 43 2004 260 268
163. M. Epstein Aldosterone as a determinant of progressive renal dysfunction: a paradigm shift. Nephrology Self-Assessment Program Am Soc Nephrol 3 2004 285 295
164. M. Epstein, V. Buckalew Jr, F. Maartinez Eplerenone 021 Investigators Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination in diabetic hypertensives with microalbuminuria Am J Hypertens 15 2002 24A (Abstr)
165. W.A. Wilmer, B.H. Rovin, C.J. Hebert Management of glomerular proteinuria a commentary J Am Soc Nephrol 14 2003 3217 3232
166. G.L. Bakris, S.C. Textor Hypertension. Nephrology Self-Assessment Program Am Soc Nephrol 4 2005 75 109
167. B.U. Ihle, J.A. Whitworth, S. Shahinfar Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency a controlled double-blind trial Am J Kid Dis 27 1996 489 495
168. J.H. Bauer, G.P. Reams, J. Hewett A randomized double-blind placebo controlled trial to evaluate the effect of enalapril in patients with clinical diabetic nephropathy Am J Kid Dis 20 1992 443 457
169. H. Buter, M.H. Hemmelder, G. Navis The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide Nephrol Dial Transplant 13 1998 1682 1685
170. A.S. Go, G.M. Chertow, D. Fan Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med 351 2004 1296 1305
171. P. Munter, J. He, L. Hamm Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States J Am Soc Neph 13 2002 745 753
172. J. Ix, M.G. Shlipak, H.H. Liu Association between renal insufficiency and inducible ischemia in patients with coronary artery disease The Heart and Soul Study J Am Soc Neph 14 2003 3233 3238
173. R.S. Wright, G.S. Reeder, C.A. Herzog Acute myocardial infarction and renal dysfunction a high-risk combination Ann Intern Med 137 2002 563 570
174. J. Al Suwaidi, D.N. Reddan, K. Williams Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes Circulation 106 2002 974 980
175. H. Reinecke, T. Trey, F. Matzkies Grade of chronic renal failure, and acute and long-term outcome after percutaneous coronary interventions Kid Intern 63 2003 696 701
176. R.N. Foley, A.M. Murray, S. Li Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999 J Am Soc Nephrol 16 2005 489 495
177. M.G. Shlipak, L.F. Fried, M. Cushman Cardiovascular mortality risk in chronic disease comparison of traditional and novel risk factors JAMA 293 2005 1737 1745
178. A. Levin, L. Stevens, P.A. McCullough Cardiovascular disease and the kidney. Tracking a killer in chronic kidney disease Postgrad Med 111 2002 1 9
179. E.M. Antman, D.T. Anbe, P.W. Armstrong ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction, executive summary a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Acute Myocardial Infarction) Circulation 110 2004 588 636
180. R. Cooper, C. Rotimi Hypertension in blacks Am J Hypertens 10 1997 804 812
181. Collaborative Studies Coordinating Center. Department of Biostatistics, School of Public Health, UNC at Chapel Hill. ARIC Surveillance Study, 1987-2000. Available at: www.cscc.unc.edu/aric/othdocs/ UNLICOMMAverageAnnualIncidenceRateTables12162003.pdf.
182. F.M. Sacks, L.P. Svetkey, W.M. Vollmer DASH-Sodium Collaborative Research Group Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet N Engl J Med 344 2001 3 10
183. A.R. Sehgal Overlap between whites and blacks in response to antihypertensive drugs Hypertension 43 2004 566 572
184. L.M. Brewster, G.A. van Montfrans, J. Kleijnen Systematic review antihypertensive drug therapy in black patients Ann Intern Med 141 2004 614 627
185. R.S. Vasan, A. Beiser, S. Seshadri Residual lifetime risk for developing hypertension in middle-aged women and men The Framingham Heart Study JAMA 287 2002 1003 1010
186. J.A. Staessen, J. Gasowski, J.G. Wang Risks of untreated and treated isolated systolic hypertension in the elderly meta-analysis of outcome trials Lancet 355 2000 865 872
187. F. Gueyffier, C. Bulpitt, J.P. Boissel INDANA Group Antihypertensive drugs in very old people: a subgroup meta-analysis of randomized controlled trials Lancet 353 1999 793 796
188. L.J. Appel, M.A. Espeland, L. Easter Effects of reduced sodium intake on hypertension control in older individuals results from the Trial of Nonpharmacologic Interventions in the Elderly (TONE) Arch Intern Med 161 2001 685 693
189. L.M. Wing, C.M. Reid, P. Ryan A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly N Engl J Med 348 2003 583 592
190. Z. Voko, M.L. Bots, A. Hofman J-shaped relation between blood pressure and stroke in treated hypertensives Hypertension 34 1999 1181 1185
191. G.W. Somes, M. Pahor, R.I. Shorr The role of diastolic blood pressure when treating isolated systolic hypertension Arch Intern Med 159 1999 2004 2009
192. G.L. Bakris, E. Gaxiola, F.H. Messerli INVEST Investigators Clinical outcomes in the diabetes cohort of the International Verapamil SR-Trandolapril study Hypertension 44 2004 637 642
193. T. Berl, L.G. Hunsicker, J.B. Lewis Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy Ann Intern Med 138 2003 542 549